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Summary Cardiovascular disease is the leading cause of death in Western countries. Since
1969, homocysteine has been implicated in the atherosclerotic process, and numerous obser-
vational studies have suggested that hyperhomocysteinaemia should be considered as an
independent cardiovascular risk factor. B-vitamins, particularly folic acid, reduce homocysteine
levels effectively; it was suggested, therefore, that supplementation with these vitamins might
decrease cardiovascular risk and reduce the morbidity and mortality associated with stroke,
coronary heart disease and peripheral artery disease. However, the results of clinical trials
conducted to investigate this issue have been inconsistent. This review discusses the ﬁndings
of these trials and provides an updated overview on the ‘homocysteine hypothesis’.
© 2009 Elsevier Masson SAS. All rights reserved.MOTS CLÉS
Homocystéine ;
Résumé La pathologie cardiovasculaire est la première cause de décès en occident. Depuis
1969, le rôle de l’homocystéine a été impliqué dans l’athérosclérose et de multiples études
observationnelles ont suggéré qu’une hyperhomocystéinémie pouvait être considérée comme unVitamines B ;Acide folique ;
Risque
cardiovasculaire ;
facteur de risque cardiovasculaire indépendant. Les vitamines B et en particulier l’acide folique
réduisent les taux d’homocystéine, et ainsi, il a été suggéré qu’une supplémentation en vita-
mines pouvait réduire le risque cardiovasculaire et ainsi la morbi-mortalité liée aux accidents
vasculaires cérébraux, à la maladie coronaire, et aux artériopathies périphériques. Cependant,
Abbreviations: CBS, cystathionine -synthetase; CHD, coronary heart disease; CVD, cardiovascular disease; IMT, intima-media
thickness; RR, relative risk.
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Accident vasculaire
cérébral ;
Maladie coronaire
les résultats des études cliniques en cours devraient éclairer ces observations initiales, qui
ne sont pas encore complètement convaincantes. Cette revue générale discute les apports
et résultats des différentes études cliniques et apporte un éclairage sur les données les plus
récentes concernant l’hypothèse de l’homocystéine, comme facteur de risque cardiovasculaire.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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els are low in people with low intake of animal proteins.
In contrast, homocysteine levels are inversely related to
vitamin intake and tend to be lower in people with a
diet rich in fruits and vegetables [53]. Alcohol increasesntroduction
n 1969, McCully was the ﬁrst to suggest that homo-
ysteine may be involved in the pathophysiology of the
therosclerotic process [1]. Since then, numerous observa-
ional studies have associated hyperhomocysteinaemia with
ardiovascular risk, and have established homocysteine as
n independent risk factor [2—21]. Folic acid and vitamins
12 and B6 are important cofactors in the metabolism of
omocysteine and have been shown to reduce elevated
omocysteine levels effectively [22—43]. It was suggested,
herefore, that supplementation with folic acid, vitamin
12 and vitamin B6 might decrease cardiovascular mortality
ubstantially — the ‘homocysteine hypothesis’ [44]. Several
arge clinical trials have been designed to test this theory.
ome of them, such as the Second Cambridge AntiOxidant
eart Study (CHAOS-2), the Vitamin Intervention for Stroke
revention (VISP) trial, the Norwegian Vitamin (NORVIT)
rial, the Heart Outcome Prevention Evaluation-2 (HOPE-2)
rial, the Homocysteinemia in Kidney and End-Stage Renal
isease (HOST) trial, the Women’s Antioxidant and Folic
cid Cardiovascular Study (WAFACS) and the Western Nor-
ay B-vitamin Intervention Trial (WENBIT) have already been
ublished, with inconsistent results. It has been suggested
hat the implementation of mandatory fortiﬁcation of cere-
ls with folic acid in the United States and Canada (aiming to
educe neural tube defects) may have inﬂuenced the results
f these trials [45]. In this review, we discuss the ﬁndings of
hese trials and attempt to provide an updated overview on
he ‘homocysteine hypothesis’.
omocysteine metabolism and causes of
yperhomocysteinaemia
omocysteine is an essential amino acid, which is
erived from the conversion of methionine to cys-
eine. homocysteine is metabolized via two pathways
Fig. 1): remethylation, in which homocysteine is recon-
erted into methionine, and transulphuration, in which
t is converted into cysteine. In the former path-
ay, homocysteine acquires a methyl group, either from
he conversion of 5-methyltetrahydrofolate into hydro-
olate or from the conversion of betaine into N,
-dimethylglycine. Vitamin B12 is an important coen-
yme in the conversion of 5-methyltetrahydrofolate into
ydrofolate and therefore for the remethylation path-
ay and the metabolism of homocysteine into methionine.
n the later pathway (transulphuration), homocysteine
s attached to a serine molecule and forms cystathio-
ine with the aid of CBS and vitamin B6, which act
s an enzyme and a coenzyme, respectively. Methion-
ne is converted into homocysteine via its conversion
nto S-adenosylmethionine (SAM), which then loses a
F
M
s
tethyl group and becomes S-adenosyl-homocysteine (SAH),
hich ﬁnally hydrolyzes into homocysteine and adenosine
46].
Serum homocysteine levels between 5 and 15mol/L
re considered to be normal. Several conditions have been
ssociated with hyperhomocysteinaemia (Table 1): the most
requent genetic defect is a mutation of the methylene
etrahydrofolate reductase (MTHFR) enzyme, which leads
o a 677 C→T substitution and is associated with mild
yperhomocysteinaemia [47]. By comparison, homozygous
eﬁciency of CBS is associated with severe hyperhomo-
ysteinaemia, up to 40-fold higher than normal [48,49].
he D919G mutation in the methionine synthase (MS) gene
resents with hyperhomocysteinaemia (200—400mol/L),
ental retardation, skeletal malformations and premature
therosclerosis [50]. Age is another important factor in
erum homocysteine levels, which increase with advanc-
ng age, possibly due to a decrease in the activity of
BS [51]. homocysteine is also increased in men com-
ared with in premenopausal women; this difference is
lso present in postmenopausal women, albeit smaller [52].
iet, particularly methionine intake, is directly associated
ith homocysteine levels. As a result, homocysteine lev-igure 1. Homocysteine metabolism. THF: tetrahydrofolate;
THFR: methylene tetrahydrofolate reductase; MS: methionine
ynthetase; SAM: S-adenosyl methionine; SAH: S-adenosyl homocys-
eine; CBS: cystathionine -synthetase.
B-vitamins and cardiovascular disease
Table 1 Causes of hyperhomocysteinaemia.
Methylene
tetrahydrofolate
reductase polymorphism
Renal insufﬁciency
677 T→G Kidney transplantation
1298 A→C Leukaemia
1317 T→C Psoriasis
Cystathionine -synthase
polymorphism
Sickle-cell anaemia
833 T→C Polycythaemia vera
919 G→A Idiopathic thrombocytosis
1730 G→A Drugs
Methionine synthetase
polymorphism D919G
Fibrates
Folic acid deﬁciency Folic acid antagonists
Vitamin B12 deﬁciency Cyclosporine
Vitamin B6 deﬁciency Methotrexate
Increasing age L-dopa
High protein intake Antiepileptics
Low intake of Metformin
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Alcohol
serum homocysteine, possibly due to interference with
folate metabolism [53]. Several drugs cause hyperhomocys-
teinaemia, such as cyclosporine [53], methotrexate [53],
ﬁbrates [54] and L-dopa [55]. Serum homocysteine is directly
associated with renal function and glomerular ﬁltration rate;
patients with end-stage renal disease (ESRD) present with
signiﬁcant hyperhomocysteinaemia [56,57]. Other causes of
hyperhomocysteinaemia include leukaemia [58], psoriasis
[59], sickle-cell anaemia [60], polycythaemia vera and idio-
pathic thrombocytosis [61].
The homocysteine hypothesis
In 1969, McCully was the ﬁrst to associate hyperhomocys-
teinaemia with atherosclerosis when he studied the cases
of two children who presented with several atheroscle-
rotic lesions and homocystinuria, and died due to ischaemic
stroke [1]. Since then, numerous observational studies
have associated hyperhomocysteinaemia with all facets of
atherosclerotic disease, such as ischaemic stroke, CHD and
peripheral artery disease [2—21]. In 1995, the meta-analysis
by Boushey et al. concluded that a 5mol/L increase in
homocysteine levels is associated with a relative risk of
1.5 (95% conﬁdence interval [CI] 1.3—1.9) for ischaemic
stroke and 1.6 (95% CI 1.4—1.7) and 1.8 (95% CI 1.3—1.9)
for CHD in men and women, respectively [62]. Similar ﬁnd-
ings were also reported in the meta-analysis by Wald et
al. in 2002 [63]. The meta-analysis of the Homocysteine
Studies Collaboration showed that a 3mol/L decrease in
serum homocysteine was linked with a 24% reduction in the
incidence of ischaemic stroke and a 16% reduction in the
incidence of CHD, whereas a 25% reduction of homocys-
teine levels reduced these risks by 19% and 11%, respectively
[2]. All these data provided strong evidence that homocys-
teine should be regarded as an independent risk factor for
atherosclerotic CVD.
n
l
w
d
o849
The next challenge was to determine the most efﬁcient
ay to lower homocysteine levels. Numerous interven-
ional studies have investigated the role of B-vitamins
B6, B12 and folic acid) in this regard [22—43]. In 2005,
he Homocysteine Lowering Trialists’ Collaboration meta-
nalysis included 25 randomized trials and 2596 patients
o test the efﬁcacy of B-vitamins [64]. It was shown that
.2mg of folic acid was associated with a 13% (95% CI 10—16)
eduction in homocysteine levels over a mean period of
months, whereas it reached a 25% (95% CI 22—28) reduc-
ion when 5mg of folic acid were administered. Vitamin
12 offered a further 5% reduction in homocysteine levels,
hereas vitamin B6 had no signiﬁcant effect. The bene-
cial effect of folic acid on serum homocysteine levels
as further conﬁrmed by Jacques et al., who reported
hat mean homocysteine concentration and prevalence of
igh homocysteine concentrations (> 13mol/L) decreased
rom 10.1 to 9.4mol/L and from 18.7% to 9.8%, respec-
ively, after the implementation of mandatory fortiﬁcation
f cereals with folic acid in the United States in 1998
65].
itamin supplementation: what is the
vidence?
arge outcome trials
n the late 1990 s, several large-scale, randomized clini-
al trials were designed and initiated to assess the effect
f B-vitamin supplementation on cardiovascular mortality
nd morbidity [66]. These trials have different charac-
eristics in terms of the population studied (fortiﬁed or
ot), the daily dose of B-vitamins, concomitant diseases
stroke/CHD/ESRD) and the duration of treatment. Table 2
ummarizes the main characteristics of the trials that have
lready published their results.
CHAOS-2 was the ﬁrst large randomized trial to be
ublished (in 2002). The investigators studied 1882 CHD
atients for a median of 1.7 years, after which the study
as terminated early. After a daily dose of 5mg folic
cid, homocysteine levels decreased from 11.2± 6.9mol/L
o 9.7± 5.3mol/L; however, there was no reduction
n the risk of composite endpoint, which consisted of
onfatal myocardial infarction, cardiovascular death or
nplanned revascularization (RR 0.97, 95% CI 0.72—1.29)
67].
The VISP trial enrolled 3680 patients with nondisabling
erebral infarction in 56 centres in the United States,
anada and Scotland between 1997 and 2001; patients were
andomized to receive a daily dose of 2.5mg folic acid,
.4mg vitamin B12 and 25mg vitamin B6 (high-dose arm) or
0g, 6g and 200g, respectively, (low-dose arm), for a
ean duration of 2 years. The trial showed that B-vitamin
upplementation had no effect on cardiovascular risk and
t was terminated prematurely. A possible reason for this
egative outcome was that the difference in homocysteine
evels between the two groups at the end of the study
as only 15% (2mol/L), which was lower than the pre-
icted value and was attributed to mandatory fortiﬁcation
f cereals with folic acid after initiation of the trial. Another
850
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ossible reason could be its modest duration (2 years)
68].
The NORVIT trial was of similar size to VISP but involved
atients with recent myocardial infarction in Norway, a non-
ortifying country. Patients were randomized to receive one
f the following four daily treatments:
0.8mg folic acid, 0.4mg vitamin B12 and 40mg vitamin B6;
0.8mg folic acid and 0.4mg vitamin B12;
40mg vitamin B6;
or placebo, for a median duration of 40 months.
The study identiﬁed a 27% reduction in serum homocys-
eine levels in patients receiving folic acid plus vitamin B12;
owever, there was no difference between groups in the pri-
ary endpoint (RR 1.08, 95% CI 0.93—1.25, p < 0.31), which
as a composite of recurrent myocardial infarction, stroke
nd sudden death attributed to coronary artery disease. Sur-
risingly, authors reported a trend towards an increased
ate of cardiovascular events among patients receiving B-
itamins, in particular the combination of folic acid, vitamin
6 and vitamin B12. As they commented, the negative results
f the trial should not be attributed to reduced compliance
r the power of the study. Although slightly underpowered
compared with the original study design), the trial still had
n 80% power to detect an 18% reduction in the primary end-
oint. The modest duration of the study could be a possible
xplanation, as well as the fact that mean baseline homo-
ysteine levels were within the normal range. However, as
he authors reported, even patients in the upper ﬁfth of
aseline homocysteine distribution (≥ 19.7mol/L) showed
o beneﬁt [69].
The HOPE-2 trial was published simultaneously with the
ORVIT trial and reported similar negative results. The
tudy enrolled 5522 patients with a history of vascular
isease or diabetes, who were randomized to receive a
aily treatment of 2.5mg folic acid, 50mg vitamin B6 and
mg vitamin B12, or placebo, for an average of 5 years.
mong them, 72.1% of patients originated from countries
ith mandatory fortiﬁcation of cereals with folic acid. The
tudy showed no beneﬁcial effect of B-vitamins on pri-
ary outcome events and death from cardiovascular causes.
owever, a signiﬁcant 24% reduction in stroke incidence
but not transient ischaemic attacks) was demonstrated in
he active treatment group (RR 0.75, 95% CI 0.59—0.97)
70].
The HOST trial was the ﬁrst study to assess the impact
f B-vitamin supplementation in patients with advanced
hronic kidney disease or ESRD. A total of 2056 partici-
ants were enrolled between 2001 and 2006 in 36 centres
n the United States for a median follow-up of 32 months.
atients were randomized to receive a daily capsule con-
aining 40mg folic acid, 100mg vitamin B6 and 2mg vitamin
12, or placebo. Despite a 25.8% reduction in serum homo-
ysteine in the active treatment group, there was no
mprovement in primary (all-cause mortality) or secondary
ndpoints, such as incidence of stroke or myocardial infarc-
ion. As the investigators suggested, the negative outcome
f HOST trial could be attributed to the fact that serum
omocysteine reached normal levels in only one-third of
atients, despite the administration of the highest vita-
in doses among all the homocysteine-lowering studies
71].
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WAFACS had the longest follow-up of all the homo-
cysteine-lowering studies as it assessed the effect of
B-vitamins (2.5mg folic acid, 50mg vitamin B6 and 1mg vita-
min B12) in 5442 women with a history of CVD or fewer than
three cardiovascular risk factors in the United States for
a median duration of 7.3 years. Once again, there was no
difference between active treatment and placebo groups
in terms of myocardial infarction, stroke, coronary revas-
cularization or cardiovascular mortality, despite an 18.5%
decrease in homocysteine levels. As with the VISP trial,
the implementation of mandatory fortiﬁcation of cere-
als with folic acid might have underpowered the study
[72].
WENBIT enrolled 3096 patients undergoing coronary
angiography in Western Norway, a non-fortifying region. Par-
ticipants were randomized to one of four groups receiving
daily oral treatment with 0.8mg folic acid, 0.4mg vitamin
B12, 40mg vitamin B6; folic acid plus vitamin B12; vita-
min B6 alone; or placebo, for a median duration of 38
months. The study was terminated early after the con-
cerns raised by the NORVIT trial over the safety of the
intervention. As with VISP, NORVIT, HOPE-2, HOST and
WAFACS, WENBIT did not demonstrate a beneﬁcial effect
of B-vitamins on total mortality or cardiovascular events.
The trial had less power than originally planned due to
lower event rates and shorter follow-up. However, it still
had an 80% power to detect a 24% reduction in the risk
of composite endpoint comprising all-cause death, nonfatal
acute myocardial infarction, acute hospitalization for unsta-
ble angina pectoris and nonfatal thromboembolic stroke
[73]. A possible explanation for the negative outcome of
the study could be that only 9.6% of participants were
hyperhomocysteinaemic [74]. As a result, despite a 30%
reduction in homocysteine levels in treatment group after
1 year of treatment, serum homocysteine was reduced
to a lower value from a higher, but still normal, value
[73].
Smaller trials, meta-analyses and
observational studies
In addition to the large-scale, randomized trials detailed
above, several smaller studies have assessed the role of
B-vitamins either directly on cardiovascular risk [75—82]
or indirectly on cardiovascular markers such as carotid
intima-media thickness (IMT) [82—91]. Wrone et al. stud-
ied 510 patients on chronic dialysis allocated to receive 1,
5 or 15mg folic acid for 2 years and found no difference
in mortality and rate of cardiovascular events. Surprisingly,
they reported an inverse relationship between homocys-
teine levels and rate of events [81]. However, another
study of 114 dialysis patients reported a positive effect
of folate on the cardiovascular event rate [79]. Liem et
al. enrolled 593 patients with stable CHD to receive a
low dose of folic acid (0.5mg daily) or placebo for 2
years in a non-fortifying region and they reported that
there was no reduction in clinical endpoints [77]. Zoungas
et al. used both carotid IMT and clinical events as pri-
mary endpoints in 315 patients with chronic renal failure
randomized to a high dose of folic acid (15mg daily) or
placebo for a median of 3.6 years, and found no reduc-
n
a
e
m
a851
ion in atheroma progression or cardiovascular morbidity or
ortality [82]. In contrast, two recent studies reported a
eneﬁcial effect of high-dose B-vitamin supplementation on
MT [85,88].
The meta-analysis by Bazzano et al. in 2006 reported
o signiﬁcant beneﬁt or harm of folic acid supplementa-
ion on the risk of CVD, CHD, stroke, or all-cause mortality
mong patients with a history of CVD or ESRD. As the
uthors commented, to date, trials have assessed the effect
f B-vitamins only in secondary prevention but not in pri-
ary prevention [92]. Indeed, the meta-analysis of Wang
t al. in 2007 showed that folic acid supplementation can
educe the risk of stroke effectively by 18% in general (RR
.82, 95% CI 0.68—1.00) and by 25% in primary preven-
ion (RR 0.75, 95% CI 0.62—0.90). Moreover, they showed
hat a greater beneﬁcial effect was seen in trials with a
reatment duration greater than 36months (RR 0.71, 95%
I 0.57—0.87), a decrease of serum homocysteine greater
han 20% (RR 0.77, 95% CI 0.63—0.94) and no fortiﬁca-
ion or partly fortiﬁed grain (RR 0.75, 95% CI 0.62—0.90)
93].
In a population-based cohort study, Yang et al. evalu-
ted trends in stroke-related mortality before and after folic
cid fortiﬁcation in the United States and Canada and, as a
omparison, during the same period in England and Wales,
here fortiﬁcation was not implemented. Interestingly, they
ound that the decrease in stroke mortality observed in the
990—1997 period in the United States and Canada, accel-
rated in the 1998—2002 period, with a change from 0.3%
o 2.9% per year. On the contrary, stroke mortality did not
hange signiﬁcantly between these two periods in England
nd Wales [94]. As authors suggested, these ﬁndings are
onsistent with the hypothesis that folic acid fortiﬁcation
ontributes to the reduction of stroke mortality and over-
ll cardiovascular risk. In this regard, cereal fortiﬁcation
ith folic acid would be an additional beneﬁt along with
he reduction of neural tube defects. Even if the cardiovas-
ular effect of folic acid fortiﬁcation is not as powerful as
as considered originally, the duration of this intervention
practically throughout life) and its wide application beyond
ocial and ﬁnancial barriers would contribute signiﬁcantly
owards cardiovascular prevention [74,95].
There are several reasons that may account for the
onﬂicting results of the trials: ﬁrstly, we should take
nto consideration that the study populations were het-
rogeneous (e.g. nondisabling cerebral infarction in VISP,
ecent myocardial infarction in NORVIT, diabetes mellitus
r vascular disease in HOPE-2). Secondly, the trial dura-
ions were short to moderate (20—88months), especially
hen B-vitamin supplementation is used as a measure
f primary prevention. Moreover, several trials (WENBIT,
AFACS) also recruited normohomocysteinaemic individu-
ls. It should also be noted that trials did not consider
atients on an individual basis, and in that sense they may
ave failed to treat the underlying cause of hyperhomocys-
einaemia (e.g. drugs). Finally, folic acid has been shown
o induce the remethylation of homocysteine to methio-
ine with increasing SAM (Fig. 1), leading to increasing
symmetrical dimethylarginine levels, which may inhibit
ndothelial nitric oxide synthase. In addition, enhancing the
ethylation pathway affects the expression of several pro-
therogenic genes [96,97].
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onclusion
here is still signiﬁcant controversy over the ‘homocysteine
ypothesis’ and the possibility that B-vitamin supplemen-
ation contributes to the prevention of CVD [98]. Several
arge-scale clinical trials have reported negative results;
ossible explanations include trial duration, as well as
he impact of folic acid fortiﬁcation on their power. Cur-
ently, more trials are being conducted and their ﬁndings
re anticipated eagerly. The preplanned meta-analysis of
hese trials will probably provide strong evidence about
he cardiovascular effect of B-vitamins and whether the
omocysteine-cardiovascular risk association is causal or
ust an epiphenomenon [99]. This meta-analysis is designed
o involve approximately 52,000 patients, with adequate
ower to detect a 10% reduction in major cardiovascu-
ar events. Moreover, it may identify speciﬁc populations
e.g. hyperhomocysteinaemic patients, primary prevention)
n which B-vitamins may be beneﬁcial. However, until then,
upplementation with B-vitamins for the prevention of CVD
s not justiﬁed.
onﬂicts of interest
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